Publication
Generative AI: A global guide to key IP considerations
Artificial intelligence (AI) raises many intellectual property (IP) issues.
Canada | Publication | July 2022
Our 2022 Guide to Canada’s Pharmaceutical Intellectual Property Regime is a convenient all-in-one reference to the important legal and regulatory regimes governing pharmaceuticals in Canada.
The Guide provides a detailed review of the key regimes, including:
We are honoured that the Guide includes a Foreword by our partner, The Right Honourable Brian Mulroney. During his tenure as the 18th Prime Minister of Canada, Mr. Mulroney championed a series of significant legislative reforms to improve protections for pharmaceuticals that continue to operate today. The COVID-19 pandemic has highlighted the importance of fostering investment in research, development and manufacturing by the innovative pharmaceutical industry in Canada. Norton Rose Fulbright’s pharmaceuticals and life sciences team understands the innovative pharmaceutical industry and will continue to work with innovators to defend their rights and maintain the benefits they bring to all Canadians.
We hope this Guide will assist in navigating the complex challenges of this rapidly evolving field.
Publication
Artificial intelligence (AI) raises many intellectual property (IP) issues.
Publication
The UK remains a world leader in offshore wind, accounting for roughly 20 percent of global offshore wind capacity, with 11.3 GW operational. It is forecast that installed capacity will rise to 19.5 GW by mid 2020s.
Publication
On 21 May 2024, the European Council (or Council) adopted the so-called ‘Hydrogen and decarbonised gas market package’ (the Gas Package). The package contains a recast of the 715/2009 gas regulation (Gas Regulation) and a recast of the 2009/73 gas directive (Gas Directive) aimed at reforming the existing EU regulatory framework to support the deployment of renewable and low-carbon gases, in particular hydrogen. As such, it represents a major development in the EU gas market.
Subscribe and stay up to date with the latest legal news, information and events . . .
© Norton Rose Fulbright LLP 2023